Preclinical evidence suggests that pharmacological inhibition of the DNA damage-sensing kinase ataxia telangiectasia and Rad3-related protein (ATR) with selective drugs like gartisertib could induce antiproliferative effects in ccRCC cells [77]. This evidence concerns the gene ATR and nonpapillary renal cell carcinoma.